MDPI and ACS Style
de Souza, L.R.; Magro, D.O.; Teixeira, F.V.; Parra, R.S.; Miranda, E.F.; Féres, O.; Saad-Hossne, R.; Soares Prates Herrerias, G.; Nisihara, R.M.; Coy, C.S.R.;
et al. Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study. Pharmaceutics 2023, 15, 586.
https://doi.org/10.3390/pharmaceutics15020586
AMA Style
de Souza LR, Magro DO, Teixeira FV, Parra RS, Miranda EF, Féres O, Saad-Hossne R, Soares Prates Herrerias G, Nisihara RM, Coy CSR,
et al. Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study. Pharmaceutics. 2023; 15(2):586.
https://doi.org/10.3390/pharmaceutics15020586
Chicago/Turabian Style
de Souza, LetÃcia Rodrigues, Daniela Oliveira Magro, Fábio Vieira Teixeira, Rogério Serafim Parra, Eron Fábio Miranda, Omar Féres, Rogério Saad-Hossne, Giedre Soares Prates Herrerias, Renato Mitsunori Nisihara, Claudio Saddy Rodrigues Coy,
and et al. 2023. "Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study" Pharmaceutics 15, no. 2: 586.
https://doi.org/10.3390/pharmaceutics15020586
